A Phase 1 Clinical Study of NXP900 in Subjects With Advanced Cancers
Nuvectis Pharma, Inc.
Nuvectis Pharma, Inc.
A2 Biotherapeutics Inc.
A2 Biotherapeutics Inc.
Novartis
Nurix Therapeutics, Inc.
Context Therapeutics Inc.
PharmaMar
Novartis
Checkpoint Therapeutics, Inc.
Aminex Therapeutics, Inc.
Multitude Therapeutics Inc.
Quadriga Biosciences, Inc.
AbbVie
AbbVie
Aduro Biotech, Inc.
Novartis
GlaxoSmithKline
Bayer
Oshadi Drug Administration
Valerio Therapeutics
INSYS Therapeutics Inc
GlaxoSmithKline
Astellas Pharma Inc
Pfizer
Anza Therapeutics, Inc.